1. Signaling Pathways
  2. Stem Cell/Wnt
  3. β-catenin

β-catenin

Beta catenin

β-catenin is a dual function protein, regulating the coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin. Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer,malignant breast tumors, ovarian and endometrial cancer. β-catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumour-suppressing APC gene. Therefore genetic mutation of the APC gene is also strongly linked to cancers, and in particular colorectal cancer resulting from familial adenomatous polyposis (FAP).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101130R
    PNU-74654 (Standard)
    Inhibitor
    PNU-74654 (Standard) is the analytical standard of PNU-74654 (HY-101130). This product is intended for research and analytical applications. PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell.
    PNU-74654 (Standard)
  • HY-W012352R
    2-Hydroxyanthraquinone (Standard)
    Inhibitor
    2-Hydroxyanthraquinone (Standard) is the analytical standard of 2-Hydroxyanthraquinone (HY-W012352). This product is intended for research and analytical applications. 2-Hydroxyanthraquinone is a product generated by the photochemical oxidation of Anthracene (ANT) (HY-Y0299). 2-Hydroxyanthraquinone induces ferroptosis in cardiomyocytes by depleting GSH and inhibiting GPX4, leading to cardiac developmental malformations. 2-Hydroxyanthraquinone causes damage to the cerebrovascular system and blood-brain barrier in zebrafish by downregulating the Wnt/β-catenin signaling pathway, as well as inducing inflammation and neuronal apoptosis. 2-Hydroxyanthraquinone can be used in studies related to cerebrovascular diseases and cardiotoxicity.
    2-Hydroxyanthraquinone (Standard)
  • HY-101090R
    KYA1797K (Standard)
    Inhibitor
    KYA1797K (Standard) is the analytical standard of KYA1797K (HY-101090). This product is intended for research and analytical applications. KYA1797K is a potent and selective Wnt/β-catenin inhibitor with an IC50 of 0.75 µM.
    KYA1797K (Standard)
  • HY-168925
    EXQ-2d
    Inhibitor
    EXQ-2d is the inhibitor for tankyrase and inhibits TNKS1 and TNKS2 with an IC50 of 48.8 nM and 13.8 nM (pIC50=7.31 and 7.86). EXQ-2d inhibits WNT/β-catenin signaling pathway with IC50 of 515 nM. EXQ-2d exhibits anti-proliferative activity in cancer cells COLO 320DM and RKO with GI50 of 4.9 μM and 77 μM.
    EXQ-2d
  • HY-B0012R
    Pamidronic acid (Standard)
    Inhibitor
    Pamidronic acid (Standard) is the analytical standard of Pamidronic acid. This product is intended for research and analytical applications. Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronic acid (Standard)
  • HY-W100287R
    Murrayafoline A (Standard)
    Inhibitor
    Murrayafoline A (Standard) is the analytical standard of Murrayafoline A (HY-W100287). This product is intended for research and analytical applications. Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
    Murrayafoline A (Standard)
Cat. No. Product Name / Synonyms Application Reactivity